Introduction
Methods
Statistical analysis
Results
Placebo (N = 9443) | Alirocumab (N = 9451) | |
---|---|---|
Any cataract-related treatment-emergent adverse event | ||
N, % (95% CI) | 134, 1.4% (1.2, 1.7) | 127, 1.3% (1.1, 1.5) |
Event rate per 100 patient-years (95% CI)a | 0.5 (0.5, 0.6) | 0.5 (0.4, 0.6) |
Hazard ratio versus placebo (95% CI)b | 0.93 (0.73, 1.20) | |
Subcategories of cataract-related treatment-emergent adverse events, N (%) | ||
Cataract | 127 (1.3%) | 116 (1.2%) |
Atopic cataract | 0 | 1 (< 0.1%) |
Cataract cortical | 2 (< 0.1%) | 1 (< 0.1%) |
Cataract nuclear | 3 (< 0.1%) | 1 (< 0.1%) |
Cataract subcapsular | 0 | 1 (< 0.1%) |
Lenticular opacities | 1 (< 0.1%) | 1 (< 0.1%) |
Cataract diabetic | 1 (< 0.1%) | 0 |
All (N = 8610) | Alirocumab (N = 4305) | Placebo (N = 4305) | |
---|---|---|---|
Age, years | 58.5 (9.3) | 58.6 (9.2) | 58.4 (9.4) |
< 65 years | 6335 (73.6%) | 3165 (73.5%) | 3170 (73.6%) |
65 to < 75 years | 1822 (21.2%) | 911 (21.2%) | 911 (21.2%) |
≥ 75 years | 453 (5.3%) | 229 (5.3%) | 224 (5.2%) |
Male | 6973 (81.0%) | 3478 (80.8%) | 3495 (81.2%) |
Race | |||
White | 6563 (76.2%) | 3262 (75.8%) | 3301 (76.7%) |
Asian | 1436 (16.7%) | 734 (17.0%) | 702 (16.3%) |
Other/unknown | 611 (7.1%) | 309 (7.3%) | 302 (7.0%) |
Hispanic or Latino | 1680 (19.5%) | 858 (19.9%) | 822 (19.1%) |
Weight, kg | 82.02 (16.68) | 81.88 (16.69) | 82.17 (16.68) |
BMI, kg/m2 | 28.29 (4.68) | 28.30 (4.70) | 28.28 (4.66) |
≥ 30 kg/m2 | 2721 (31.8%) | 1344 (31.4%) | 1377 (32.1%) |
Region | |||
Asia | 1359 (15.8%) | 689 (16.0%) | 670 (15.6%) |
South America | 1443 (16.8%) | 734 (17.0%) | 709 (16.5%) |
Eastern Europe | 2290 (26.6%) | 1124 (26.1%) | 1166 (27.1%) |
Western Europe | 1869 (21.7%) | 921 (21.4%) | 948 (22.0%) |
North America | 1088 (12.6%) | 55 (12.9%) | 534 (12.4%) |
Rest of world | 561 (6.5%) | 283 (6.6%) | 278 (6.5%) |
All (N = 8610) | Alirocumab (N = 4305) | Placebo (N = 4305) | |
---|---|---|---|
LDL-C, mmol/L | 2.1 ± 0.6 | 2.1 ± 0.6 | 2.16 ± 0 |
Non-HDL-C, mmol/L | 2.9 ± 0.7 | 2.9 ± 0.7 | 2.9 ± 0.7 |
Total cholesterol, mmol/L | 4.0 ± 0.8 | 4.0 ± 0.8 | 4.0 ± 0.8 |
HDL-C, mmol/L | 1.1 ± 0.3 | 1.1 ± 0.3 | 1.1 ± 0.3 |
Fasting triglycerides, mmol/L | 1.8 ± 1.0 | 1.8 ± 1.0 | 1.8 ± 1.1 |
Lipoprotein(a), mg/dL | 28.6 ± 33.1 | 28.7 ± 33.3 | 28.7 ± 33.2 |
Apolipoprotein B, mg/dL | 77.6 ± 17.3 | 78.1 ± 17.5 | 77.9 ± 17.4 |
Apolipoprotein A1, mg/dL | 131.6 ± 23.0 | 131.2 ± 22.5 | 131.4 ± 22.7 |
Apolipoprotein B/Apolipoprotein A1 ratioa | 0.61 ± 0.2 | 0.61 ± 0.2 | 0.61 ± 0.2 |
Total cholesterol/HDL-C ratioa | 3.8 ± 1.0 | 3.8 ± 1.0 | 3.8 ± 1.0 |
All (N = 3128) | Alirocumab (N = 782) | Placebo (N = 2346) | |
---|---|---|---|
Age, years | 58.8 ± 9.5 | 58.9 ± 9.4 | 58.7 ± 9.5 |
< 65 | 2243 (71.7) | 557 (71.2) | 1686 (71.9) |
65 to < 75 | 711 (22.7) | 184 (23.5) | 527 (22.5) |
≥ 75 | 174 (5.6) | 41 (5.2) | 133 (5.7) |
Male | 2526 (80.8) | 645 (82.5) | 1881 (80.2) |
Race | |||
White | 1928 (61.6) | 461 (59.0) | 1467 (62.5) |
Asian | 951 (30.4) | 253 (32.4) | 698 (29.8) |
Other/unknown | 249 (8.0) | 68 (8.7) | 181 (7.7) |
Hispanic or Latino | 752 (24.0) | 192 (24.6) | 560 (23.9) |
Weight, kg | 77.9 ± 16.5 | 76.9 ± 16.6 | 78.2 ± 16.4 |
BMI, kg/m2 | 27.3 ± 4.5 | 27.2 ± 4.5 | 27.4 ± 4.4 |
≥ 30 kg/m2 | 784 (25.1) | 191 (24.4) | 593 (25.3) |
Region | |||
Asia | 919 (29.4) | 240 (30.7) | 679 (28.9) |
South America | 710 (22.7) | 178 (22.8) | 532 (22.7) |
Eastern Europe | 665 (21.3) | 157 (20.1) | 508 (21.7) |
Western Europe | 343 (11.0) | 81 (10.4) | 262 (11.2) |
North America | 336 (10.7) | 85 (10.9) | 251 (10.7) |
Rest of world | 155 (5.0) | 41 (5.2) | 114 (4.9) |
All (N = 3128) | Alirocumab (N = 782) | Placebo (N = 2346) | |
---|---|---|---|
LDL-C, mmol/L | 2.0 ± 0.5 | 2.0 ± 0.6 | 2.0 ± 0.5 |
Non-HDL-C, mmol/L | 2.8 ± 0.7 | 2.8 ± 0.7 | 2.8 ± 0.6 |
Total cholesterol, mmol/L | 3.9 ± 0.7 | 3.9 ± 0.8 | 3.9 ± 0.7 |
HDL-C, mmol/L | 1.1 ± 0.3 | 1.1 ± 0.3 | 1.1 ± 0.3 |
Fasting triglycerides, mmol/L | 1.8 ± 1.1 | 1.8 ± 0.9 | 1.8 ± 1.1 |
Lipoprotein(a), mg/dL | 18.8 ± 23.1 | 19.3 ± 22.4 | 18.7 ± 23.3 |
Apolipoprotein B, mg/dL | 75.4 ± 16.0 | 76.0 ± 17.5 | 75.2 ± 15.4 |
Apolipoprotein A1, mg/dL | 129.9 ± 22.9 | 129.2 ± 22.3 | 130.1 ± 23.1 |
Apolipoprotein B/Apolipoprotein A1 ratioa | 0.6 ± 0.2 | 0.6 ± 0.2 | 0.6 ± 0.2 |
Total cholesterol/HDL-C ratioa | 3.7 ± 1.0 | 3.7 ± 0.9 | 3.7 ± 1.0 |